Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX.
Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types.
BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule.
Shares of BNTX surged on the deal announcement.
Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%.
More on BMY & BNTX Agreement
Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products.
Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028.
BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
Both the companies will jointly share development and manufacturing costs along with profits on an equal basis.
BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC).
A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025.
Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types.
BMY Looks to Diversify Business
BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition.
BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy.
The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years.
BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price.
The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints.
The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia.
Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment.
In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299.
The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025.
BMY's Zacks Rank & Stocks to Consider
Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year.
Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Bristol Myers Squibb Company (BMY): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30 minutes ago
- Globe and Mail
Trump travel ban could damage longstanding relations with African countries, leaders warn
The latest sweeping travel ban imposed by U.S. President Donald Trump could damage relations with African countries that have taken decades to build, African leaders say. Mr. Trump announced on Wednesday night that his administration is banning all visits to the United States by citizens from 12 countries, including seven African states. He also introduced restrictions on entry by citizens from seven other countries, including three in Africa. Trump issues travel ban for a dozen countries set to go into effect Monday The African Union Commission, the AU's administrative branch, reacted swiftly on Thursday, voicing alarm at the Trump announcement. It said it was 'concerned about the potential negative impact of such measures on people-to-people ties, educational exchange, commercial engagement, and the broader diplomatic relations that have been carefully nurtured over decades.' The AU Commission appealed to the Trump administration to adopt a more 'consultative approach' and to engage in dialogue with the affected countries. It urged Washington to act in a 'balanced' and 'evidence-based' manner. The travel ban, set to take effect on Monday, would ban visitors from Sudan, Somalia, Libya, Chad, Haiti, Afghanistan, Iran, Yemen, Myanmar, the Republic of Congo, Equatorial Guinea and Eritrea. Several countries on this list – including Sudan, Somalia, Myanmar, Yemen and Libya – have suffered huge damage from armed conflicts or militia violence in recent years, with large numbers of refugees fleeing from their wars. In some cases, their official governments do not control all of their territory, making it impossible for them to comply with U.S. demands for screening and vetting of their travellers. Trump suspends visas for foreign students seeking to attend Harvard The policy will also increase restrictions on visitors from Burundi, Sierra Leone, Togo, Venezuela, Cuba, Laos and Turkmenistan. Mr. Trump complained that some countries have deficient screening processes and are reluctant to take back their citizens if they exceed the time limits on their U.S. visas. 'We don't want them,' he said.
Globe and Mail
30 minutes ago
- Globe and Mail
Protect the sacred space of leisure from being contaminated by work
Interested in more careers-related content? Check out our new weekly Work Life newsletter. Sent every Monday afternoon. Gloria Mark, a leading researcher on attention and distraction and University of California informatics professor, warns us to beware of leisure contamination: The tendency while taking a break to still be wrestling with work and family responsibilities. It's a mental spillover of stress into those rare moments that are meant to be restful. 'Psychological detachment – fully detaching from stressors during leisure time – is crucial for recovery from stress. But achieving it in our always-connected, always-on, busy culture is getting harder and harder to do,' she writes on her Substack blog. Most of us believe leisure time has been shrinking. But she says the quantity has remained constant over the past 20 years; what has changed is how we spend it, with an extra two hours spent watching screens – smartphones, other personal devices and television. Despite leisure time remaining consistent, however, stress levels have risen sharply. 'Even when we set aside time to relax, we often don't take full advantage of it, allowing our minds to remain tethered to screens, work or other responsibilities. It's like a faucet that never fully turns off – a steady drip, drip, drip of stress that contaminates our leisure time. All kinds of external pressures like demanding jobs, financial concerns, social expectations and disturbing world events in the news intrude on our rest, preventing the mental and emotional recovery that leisure time is meant to provide,' she says. To reduce leisure contamination, she advises us to consciously separate work from leisure. That means no emails or messages and no thinking about your next report during downtime. 'Leisure must be protected as a distinct and sacred space,' she says. Approach leisure time with intention. Consider it a valuable resource, not just filler time. Choose activities that rejuvenate you. 'Despite having the time to unwind, many of us squander it – not by choice, but because of ingrained habits and external intrusions,' she writes. For many people, the biggest block of continuous leisure time is our vacations. It can be hard to avoid contamination and in some cases nearly impossible. Maybe you're a sole entrepreneur or a lawyer prepping for a big trial or someone else with an important, upcoming critical deadline. It may be even more important in those situations to ensure refreshing time away, in essence avoiding contamination in the part of the vacation that must be contaminated. Time management coach Elizabeth Grace Saunders says that delicate balance starts with telling people you are away – on vacation. Your instinct may be the opposite but an out-of-office responder reduces your worry about what others are thinking when you don't react quickly to them. You also want to avoid compulsively checking your messages to ensure no emergency is occurring. 'For any days where you're not working the full day, have a designated person who can field most items and contact you if a true emergency comes up. Prep them on exactly when you want to be contacted,' she writes in Harvard Business Review. Don't leave your work hours undefined on the break. To the extent that you can, determine your work start and stop times in advance for your own sake and those of people travelling with you. 'I recommend frontloading any longer stretches of work while you have momentum from having just left the office, then tapering down so you feel like you can get more and more relaxed throughout your travels,' she says. If you need to commit to fixed meeting times, arrange them for the start of the day because you will have less control of what happens as the day unfolds and delays occur or plans change with the weather or impulse. Finally, resist opening messages on non-urgent, non-critical items. 'To have space in your schedule to relax, you need to do less than you would if you were in the office. If you're travelling but still doing some work, it's tempting to answer a random question, help someone out or otherwise participate in non-urgent work items 'real quick.' But if you want to feel like you took some real time off, you can't engage in everything you typically would in the office,' she warns. Quick Hits Harvey Schachter is a Kingston-based writer specializing in management issues. He, along with Sheelagh Whittaker, former CEO of both EDS Canada and Cancom, are the authors of When Harvey Didn't Meet Sheelagh: Emails on Leadership.
Globe and Mail
30 minutes ago
- Globe and Mail
What is Trump's new travel ban and which countries are affected? Here's what to know
Citing national security concerns, U.S. President Donald Trump on Wednesday banned citizens of 12 countries, primarily in Africa and the Middle East, from entering the United States and restricted access for citizens of seven other nations, resurrecting and expanding a hallmark policy of his first term. Here's what to know about the new rules. The travel ban applies to citizens of Afghanistan, Myanmar, Chad, the Republic of Congo, Equatorial Guinea, Eritrea, Haiti, Iran, Libya, Somalia, Sudan and Yemen. The policy change restricts entry for citizens of Burundi, Cuba, Laos, Sierra Leone, Togo, Turkmenistan and Venezuela who are outside the U.S. and do not hold a valid visa. The policy takes effect Monday at 12:01 a.m. and does not have an end date. Since returning to the White House, Trump has launched an unprecedented campaign of immigration enforcement that has pushed the limits of executive power and clashed with federal judges trying to restrain him. The travel ban results from a Jan. 20 executive order Trump issued requiring the departments of State and Homeland Security and the Director of National Intelligence to compile a report on 'hostile attitudes' toward the U.S. The aim is to 'protect its citizens from aliens who intend to commit terrorist attacks, threaten our national security, espouse hateful ideology, or otherwise exploit the immigration laws for malevolent purposes,' the administration said. In a video released on social media, Trump tied the new ban to a terror attack Sunday in Boulder, Colo., saying it underscored the dangers posed by some visitors who overstay visas. The suspect in the attack is from Egypt, a country that is not on Trump's restricted list. The Department of Homeland Security says he overstayed a tourist visa. Trump said nationals of countries included in the ban pose 'terrorism-related' and 'public-safety' risks, as well as risks of overstaying their visas. He also said some of these countries had 'deficient' screening and vetting or have historically refused to take back their own citizens. His findings rely extensively on an annual Homeland Security report of visa overstays of tourists, business visitors and students who arrive by air and sea, singling out countries with high percentages of remaining after their visas expired. 'We don't want them,' Trump said. The inclusion of Afghanistan angered some supporters who have worked to resettle its people. The ban makes exceptions for Afghans on Special Immigrant Visas, generally people who worked most closely with the U.S. government during the two-decade war there. The list can be changed, the administration said in a document circulated Wednesday evening, if authorities of designated countries make 'material improvements' to their own rules and procedures. New countries can be added 'as threats emerge around the world.' International aid groups and refugee resettlement organizations roundly condemned the new ban. 'This policy is not about national security – it is about sowing division and vilifying communities that are seeking safety and opportunity in the United States,' said Abby Maxman, president of Oxfam America. Trump travel ban could damage longstanding relations with African countries, leaders warn The African Union Commission expressed concern Thursday about the 'the potential negative impact' of the ban on educational exchanges, business ties and broader diplomatic relations. 'The African Union Commission respectfully calls upon the U.S. administration to consider adopting a more consultative approach and to engage in constructive dialogue with the countries concerned,' the commission said in a statement. During his first term, Trump issued an executive order in January, 2017, banning travel to the U.S. by citizens of seven predominantly Muslim countries including Iraq, Syria, Iran, Sudan, Libya, Somalia and Yemen. It was one of the most chaotic and confusing moments of his young presidency. Travellers from those nations were either barred from getting on their flights to the U.S. or detained at U.S. airports after they landed. They included students and faculty, as well as business people, tourists and people visiting friends and family. The order, often referred to as the 'Muslim ban' or the 'travel ban,' was retooled amid legal challenges until a version was upheld by the Supreme Court in 2018. The ban affected various categories of travellers and immigrants from Iran, Somalia, Yemen, Syria and Libya, plus North Koreans and some Venezuelan government officials and their families.
